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Abstract 
Background  
Clinical translation of immunohistochemistry (IHC) biomarkers requires reliable 
and reproducible cut-offs or thresholds for interpretation of immunostaining. 
Most IHC biomarker research focuses on the clinical relevance (diagnostic, 
prognostic or predictive utility) of cut-offs, with less emphasis on observer 
agreement using these cut-offs. From the literature, we identified three 
commonly used cut-offs  of 10% positive epithelial cells, 20% positive epithelial 
cells and moderate to strong staining intensity (+2/+3 hereafter) to use for 
investigating observer agreement.  
Materials and Methods 
A series of 36 images of microarray cores stained for four different IHC 
biomarkers, with variable staining intensity and percentage of positive cells, was 
used for investigating inter- and intra-observer agreement. Seven pathologists 
scored the immunostaining in each image using the three cut-offs for positive 
and negative staining. Kappa statistic was used to assess the strength of 
agreement for each cut-off.  
Results 
The inter-observer agreement between all seven pathologists using the three 
cut-offs was reasonably good, with mean κ scores 0.64, 0.59 and 0.62 
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respectively for 10%, 20% and +2/+3 cut-offs. A good agreement was observed 
for experienced pathologists using the 10% cut-off and their agreement was 
statistically higher than for junior pathologists (p=0.02). In addition, the mean 
intra-observer agreement for all seven pathologists using the three cut-offs was 
reasonably good, with mean κ scores 0.71, 0.60 and 0.73 respectively for 10%, 
20% and +2/+3 cut-offs. For all three cut-offs, a positive correlation was 
observed with perceived ease of interpretation (p<0.003). Finally, cytoplasmic-
only staining achieved higher agreement using all three cut-offs than mixed 
staining patterns. 
Conclusions 
All three cut-offs investigated achieve reasonable strength of agreement 
modestly decreasing inter and intra-observer variability in IHC interpretation. 
These cut-offs have previously been used in cancer pathology and this study 
provides evidence that these cut-offs can be reproducible between practising 
pathologists. 
Keywords 
Observer agreement, Kappa, immunohistochemistry, biomarker, cut-off 
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Introduction 
The use of immunohistochemistry (IHC) biomarkers for clinical decision making is 
an important research field with significant translational potential. A multitude 
of biomarkers for a variety of cancers is available and a large literature exists on 
novel biomarker discovery, but only a minority impact upon patient care. 
Amongst other reasons, one barrier to clinical translation of biomarkers is the 
lack of a standardised cut-off or threshold for interpretation of IHC staining1,2. 
Evaluation of immunostaining is important in translational studies assessing 
biomarker expression for diagnostic, prognostic or predictive purposes.  
Biomarker expression assessment usually employs a continuous or ordinal scale; 
but for meaningful clinical use it is usually dichotomised and a cut-off 
established for assigning a patient into either positive/negative expression 
category or high/low expression category 3. In addition, for some biomarkers, 
more than two categories may be required for example the ‘Allred score’ for 
estrogen receptor positivity 4. For clinical translation, there are two main issues 
in the development and application of a standardised cut-off for IHC biomarkers. 
One is the identification of an appropriate cut-off that provides suitable 
sensitivity/specificity for diagnostic biomarkers or that stratifies patients based 
on survival and response to treatment for prognostic and predictive biomarkers 
respectively. The other issue is to assess the inter- and intra-observer agreement 
in the interpretation of a cut-off threshold. One potential strategy to address 
the former is the use of a receiver operating characteristics (ROC) curve that can 
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help to identify an appropriate cut-off 1,5. The latter issue can be answered by 
assessing the level of agreement between pathologists 6-8.  
There is currently no standardized cut-off for diagnostic IHC biomarkers. Most of 
the reported cut-offs are purposive that best fit cancer or normal groups. These 
cut-offs are based on the intensity of staining or percentage of positive cells or 
on a combination of both intensity and percentage in terms of immunoreactive 
scores, H scores and “quick” scores 7,9-13.  
Two widely used cut-offs reported in the literature for IHC diagnostic biomarkers 
are positive/negative staining (e.g. p16/Ki-67 staining for the diagnosis of 
cervical intra-epithelial neoplasia 3) and 10% positive epithelial cells (e.g. a 
panel of napsin A, TTF 1, CK 5, and p63 in differentiating adenocarcinoma from 
squamous cell carcinoma of the lung) 14-19. Other reported cut-offs are: more 
than 30% cells with uniform, intense membranous staining of invasive tumour 
cells for human epidermal growth factor receptor 2 (HER2) (positive HER2 
staining in breast cancer) 20; and more than 5% positive tumour cells for CK 7 and 
CK 20 (differential diagnosis in metastatic carcinoma of unknown origin) 21. 
These scoring systems and cut-offs have been adopted for research purposes.  
Some of them are used in clinical practice; but studies looking at their 
reproducibility between pathologists are few. A cut-off should be both clinically 
relevant and easily interpretable by pathologists. There is a tendency to focus 
more on the clinical relevance of the cut-off for a biomarker with less focus on 
the level of agreement between pathologists when they use it for scoring 
purposes 6,22. Inter- and intra-observer variation of a cut-off is infrequently 
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analysed despite the fact that it is recognised as a potential barrier to clinical 
translation. 
We selected three cut-offs for investigation based on our diagnostic IHC work 23 
and the wider IHC literature. These cut-offs are 10% positive epithelial cells (10% 
hereafter), 20% positive epithelial cells (20% hereafter) and moderate to strong 
staining intensity with any proportion of positive cells (+2/+3 hereafter) 8,14,17,23-
27. These cut-offs are clinically relevant and we postulated that they are easily 
interpretable and reproducible amongst pathologists. The aims of the current 
study were to investigate the cut-offs (10%, 20% and +2/+3) for inter- and intra-
observer agreement; and to explore factors influencing agreement between 
pathologists for IHC cut-offs. 
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Materials and Methods 
Immunohistochemistry images and participants 
A series of 36 images of pancreatic ductal adenocarcinoma (PDAC) tissue 
microarray cores for four diagnostic IHC biomarkers (nine images each from KOC, 
maspin, mesothelin and S100P) were used for this study. These cores have 
previously been studied for diagnostic utility 23. These cores were carefully 
selected for each biomarker based on a variable range of staining intensity and 
proportion of positive cells. Some cores with no immunostaining were also 
included. The purpose of using images from one type of tumour i.e. PDAC was to 
allow the observers to concentrate on the immunostaining cut-offs rather than 
interpreting the morphology of different tumours. KOC expression was 
cytoplasmic; maspin has both cytoplasmic and nuclear expression but the 
pathologists were asked to score only cytoplasmic staining for maspin and 
disregard nuclear staining; mesothelin expression was cytoplasmic and/or 
membranous; and S100P expression was cytoplasmic and/or nuclear. Seven 
pathologists (three experienced pathologists and four junior pathologists) 
participated in the study. Experienced pathologists have clinical pathology 
experience of more than 15 years, while junior pathologists have 3-7 years of 
experience. All pathologists were sufficiently trained to evaluate pancreatic 
tumours. Pathologists were coded as A, B, C, D, E, F and G. Ethical approval has 
been granted by the North Glasgow University Hospitals NHS Trust Ethics 
Committee and by the National Health Service Greater Glasgow and Clyde Ethics 
Committee. This ethics approval includes the use of archival pathology 
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specimens, where the patients were not given the opportunity to donate their 
tissue. 
Scoring the IHC cut-offs 
The 36 images were shown via projection on Powerpoint, and were arranged 
based on biomarkers with reference staining intensities (weak, moderate, 
severe) provided at the start for each biomarker. A scoring sheet with 
instructions on scoring was prepared with the help of pathology colleagues 
(Supplementary Table 1). All the participating pathologists participated in one 
session for the inter-observer part of the study. After a short presentation (5-10 
min) on the purpose of this study, the scoring sheets were distributed between 
all seven pathologists. Each image was shown for one minute. The pathologists 
were asked to interpret the immunostaining of each image for the three cut-offs 
as a binary categorical variable, “present” or “absent”. The three cut-offs were: 
10%, 20% and +2/+3 cut-offs. For example, a 10% cut-off is “present” when more 
than or equal to 10% epithelial cells are positive in the desired subcellular 
compartment and is “absent” when fewer than 10% epithelial cells are positive. 
Each core was also recorded as being easy (1) or challenging (2) to score.  
All seven pathologists participated in the intra-observer part of the study three 
weeks after the inter-observer session. The tissue core images shown were the 
same, but arranged in a different order to minimise recall bias. 
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Statistics and data analysis 
We used kappa (κ) scores as a measure of the strength of agreement between 
pathologists for all three cut-offs. Kappa scores reflect the strength of 
agreement between observations, adjusted for chance agreement, and can 
range from 0 to 1. We used the standards suggested by Landis and Koch 28 for the 
interpretation of strength of agreement. Kappa scores are shown in six 
categories from 0-1 and each category is colour coded (Supplementary Table 2).  
Inter-observer agreement: to determine inter-observer agreement for each of 
the three cut-offs, each pathologist’s interpretation of immunostaining was 
compared with that of the other pathologists in a pair-wise manner. 21 inter-
observer (AB, AC, AD and so on…) κ scores were generated for each of the three 
cut-offs (10%, 20% and +2/+3). Finally a mean inter-observer κ score for each 
cut-off was used as a measure of strength of agreement between pathologists. 
Impact of pathologists’ experience and antibody staining pattern on inter-
observer agreement: for each cut off, mean inter-observer κ scores were 
calculated for experienced pathologists and for junior pathologists and then 
compared. The staining pattern was noted for the antibody used in each slide 
and mean k scores calculated for each staining pattern. The aim was to 
determine if the pathologists tend to have more agreement for a particular 
staining pattern (cytoplasmic, nuclear and/or membranous).  
To determine whether these three cut-offs are statistically different from each 
other, the paired sample t test (for large sample size) and Wilcoxon signed 
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ranked test (for small sample size) were used to compare the pairwise k scores. 
To determine which cut-off is most easily scored, these three cut-offs as 
predictor variables were put in a linear regression model against perceived ease 
of scoring as a dependent variable.  
Intra-observer agreement: to determine reproducibility of these three cut-offs, 
kappa scores were generated comparing scoring and re-scoring of the same 
image arranged in different orders three weeks apart for each pathologists. 
Kappa scores were generated for all seven pathologists (A-A, B-B, C-C, D-D, E-E, 
F-F and G-G) using the three cut-offs. Seven intra-observer agreements were 
generated for each cut-off. A mean intra-observer κ score for each cut-off was 
then used as a measure of strength of agreement. 
A p value <0.05 was considered statistically significant. SPSS version 21 was used 
for statistical analyses. 
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Results 
Taken together, 1512 evaluations were made in the inter- and intra-observer 
sessions by the pathologists. The average time for interpretation of an image 
was roughly 30-45 seconds. Results are divided into three parts: inter-observer 
agreement; perceived ease of scoring; and intra-observer agreement.  
Inter-observer agreement 
All seven pathologists 
The mean inter-observer κ scores were 0.64, 0.59 and 0.62 for 10%, 20% and 
+2/+3 cut-offs respectively (Table 1). The mean κ score agreement for 10% and 
+2/+3 cut-offs is in the ‘substantial’ agreement category and for the 20% cut-off 
is in the ‘moderate’ agreement category. However, the κ score agreements 
between the three cut-offs were not statistically different from each other 
(Supplementary Figure 1). 
Figure 1 shows examples of IHC images used in this study. Images with low 
observer agreement have either weak staining intensity, or the proportion of 
positively stained cells is lower compared to images with high level agreement. 
In fact, tissues with both strong staining intensity and a higher percentage of 
positive cells have higher agreement regardless of the biomarker and staining 
pattern. 
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In summary, the inter-observer agreements between all seven pathologists for 
the three cut-offs were reasonably good. In addition, the agreements for the 
cut-offs were not statistically different from each other.  
Impact of pathologists’ experience on inter-observer agreement  
The mean inter-observer κ scores for experienced pathologists were 0.81, 0.70 
and 0.55 for 10%, 20% and +2/+3 cut-offs respectively (Table 2A). The mean 
inter-observer κ scores for junior pathologists were 0.61, 0.60 and 0.73 for 10%, 
20% and +2/+3 cut-offs respectively (Table 2B). The agreement on 10% cut-off is 
statistically higher for the experienced pathologists than the junior pathologists 
(P=0.02, Mann-Whitney U test). However, no statistically significant difference 
between experienced and junior pathologists was observed for 20% and +2/+3 
cut-offs. 
In summary, a higher level of agreement was observed for experienced 
pathologists using 10% cut-off and this was statistically higher than junior 
pathologists.  
Impact of antibody staining pattern on inter-observer agreement  
In the images studied, there were three staining patterns: cytoplasmic only 
staining; cytoplasmic and/or nuclear staining (CN); and cytoplasmic and/or 
membranous staining (CM).  
The mean κ scores for cytoplasmic only staining were higher than the other 
staining patterns. More specifically, a statistically higher agreement for 
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cytoplasmic only staining was observed in the following scenarios: cytoplasmic 
compared to CN category using +2/+3 cut-off; and cytoplasmic compared to CM 
category using 20% and +2/+3 cut-offs.  
Moreover, a statistically higher agreement for CN staining was observed in the 
following scenarios: CN compared to CM category using 20% and +2/+3 cut-offs. 
No statistically significant difference between different staining patterns was 
observed for the 10% cut-off (Table 3). 
In summary, there is more inter-observer agreement for cytoplasmic only 
staining followed by CN and CM. Finally the 10% cut-off appears to yield good 
inter-observer agreement irrespective of the staining compartment of cell. 
Relationship between cut-offs and perceived ease of 
scoring  
A positive correlation was observed between all three cut-offs and perceived 
ease of scoring (p<.0001). However, in a multivariate analysis the 10% cut-off 
(β=0.41, p<0.001) was more easily scored as compared to the +2/+3 cut-off 
(β=0.38, p=0.001) or the 20% cut-off (β=0.34, p=0.004) (Table 4).  
Interestingly, the pattern emerging from this correlation, that 10% is relatively 
more easily scored, followed by +2/+3 and 20%, supports the mean inter- and 
intra-observer κ scores for these cut-offs (Table 1 and Table 5). 
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Intra-observer agreements 
The mean intra-observer κ scores were 0.71, 0.60 and 0.73 for 10%, 20% and 
+2/+3 cut-offs respectively (Table 5). The κ score agreement for 10% and +2/+3 
cut-offs is in the ‘substantial’ agreement category and for the 20% cut-off is in 
the ‘moderate’ agreement category. However, the κ score intra-observer 
agreements between all seven pathologists for the three cut-offs were not 
statistically different (Supplementary Figure 2).  
In summary, the intra-observer agreements for the three cut-offs were 
reasonably good. In addition, the agreements for the three cut-offs were not 
statistically different from each other. Thus a good intra-observer agreement 
confirms the reproducibility of these cut-offs by pathologists and again this 
supports their use for IHC biomarkers. 
The inter- and intra-observer agreements follow the same pattern i.e. 
‘substantial’ agreement for 10% and +2/+3 and ‘moderate’ agreement for 20% 
cut-offs. 
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Discussion 
Three IHC cut-offs, namely 10%, 20% and +2/+3 were assessed for observer 
agreement between pathologists. All cut-offs demonstrated good inter- and 
intra-observer agreement between pathologists. Similarly, all three cut-offs 
showed high correlation with perceived ease of scoring. Finally, the observer 
agreement for cytoplasmic only staining was higher than cytoplasmic/nuclear 
staining and cytoplasmic/membranous staining. 
Establishing a cut-off for biomarker assessment is an essential pre-requisite for 
clinical translation. A wide range of cut-offs have been used for diagnostic, 
prognostic and predictive IHC biomarkers in research and clinical settings. The 
purpose of a cut-off for a diagnostic biomarker is to assign patients into positive 
or negative categories with reasonable sensitivity without compromising 
specificity 29. Based on the expression level for a candidate biomarker in cancer 
and normal tissue, a cut-off is established. A good diagnostic cut-off has a low 
probability of false positivity and false negativity 29. The purpose of a cut-off for 
a prognostic biomarker is to divide the population into categories of longer and 
shorter survival for the outcome. In research settings a cut-off based on 
percentage of positive tumour cells is mostly used 30,31. Similarly, the aim of a 
cut-off for predictive biomarkers is to stratify patients into likely responders and 
non-responders to treatment and intervention 32.  
IHC cut-offs used for prognostic and predictive biomarkers have been 
investigated for observer agreement but such studies are limited for diagnostic 
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biomarkers. The cut-offs of 10% and 30% positive cells with strong membranous 
staining for HER2 have been investigated for reproducibility amongst 
pathologists 8. In addition, for oestrogen receptor (ER) and progesterone 
receptor (PR), the continuous H-score (range 0-300) and categorical scores 
(negative: H-score<1, positive: H-score ≥1) have been investigated for inter-
observer agreement 7. These cut-offs for HER2, PR and ER are clinically 
important and are used in clinical practice by pathologists.  
Clinically relevant cut-offs are important for biomarker evaluation. We sought to 
investigate three cut-offs i.e. 10%, 20% and +2/+3 with the hope that if evidence 
of their scoring reproducibility is provided, they could potentially help the 
clinical translation of IHC biomarkers. Interestingly, the purpose of cut-offs 
differ for different biomarkers but these three cut-offs have been used for 
diagnostic (S100P, pVHL, KIT, HMGI(Y), CK20, P53, Ki-67) 17,26,27,33,34, prognostic 
(Ki-67, p53) and predictive (APAF-1, EGFR) biomarkers 35-38. Therefore, 
investigating the strength of agreement between pathologists for these three 
cut-offs has significant clinical importance. 
Inter-observer agreement between pathologists was used to elucidate the 
reliability of cut-offs. A ‘substantial’ agreement was observed with overall mean 
κ scores of 0.64 and 0.62 for 10% and +2/+3 cut-offs respectively, whereas 
‘moderate’ agreement with a κ score of 0.59 was observed for 20% cut-off. In a 
study comparing the 10% positivity with 30% positivity for HER2, the mean κ 
scores for inter-observer agreement were 0.49 for 10% positive cells and 0.54 for 
30% positive cells 8. Clearly, the κ scores generated for the three cut-offs under 
investigation in our project are comparable to the k scores for HER2 which is 
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already in clinical practice as a predictive biomarker. Moreover, studies looking 
at the inter-observer reproducibility in histopathology and the IHC literature 
have shown that κ scores more than 0.60 (substantial agreement) are regarded 
as a good level of agreement. In comparison, κ scores less than 0.40 (fair 
agreement) are regarded as an unacceptably low level of agreements for 
diagnostic purposes 39-43. 
Intra-observer agreement of the scoring and then re-scoring of the same image 
was used to assess reproducibility of the cut-offs. Again a pattern similar to 
inter-observer agreement emerged with ‘substantial’ agreements for the 10% 
and +2/+3 cut-offs and ‘moderate’ agreement for 20% cut-off. However, the 
intra-observer agreements (0.71, 0.60 and 0.73) in the present study are higher 
than inter-observer agreements (0.64, 0.59 and 0.62) for the three cut-offs. This 
finding agrees with the previous literature that the intra-observer agreement is 
more than the inter-observer agreement. For example the intra-observer 
agreement (κ=0.85) is better than the inter-observer agreement (κ=0.80) for 
PDX-1 IHC staining intensity in prostate cancer 44. In addition, the intra-observer 
agreement (κ=0.78) is better than the inter-observer agreement (κ=0.65) for 
evaluation of focal cortical dysplasia categories 45.  
Taking 10% positive cells as a cut-off has been used for a variety of IHC 
biomarkers in different cancer types. These include S100P and XIAP in the 
differentiation of pancreatic cancer from non-neoplastic pancreatic tissue, and 
for a panel of napsin A, TTF 1, CK 5, and P63 in differentiating adenocarcinoma 
from squamous cell carcinoma of the lung 19,46. Moreover, 10% cut-off is 
prognostic in breast cancer for a panel of Ki67 and p53, predictive of event-free 
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survival in stage II colon cancer for VEGF and is predictive in rectal tumours 
treated with preoperative, high-dose-rate brachytherapy for APAF-1 36,38,47.  The 
use of a 10% cut-off in other areas of pathology means that the more 
experienced pathologists in the present study will have already had experience 
in applying this cut-off, which is a possible explanation for why they have a 
higher agreement than junior pathologists. Studies have attempted to show the 
reproducibility of the 10% cut-off and the κ scores achieved in the current study 
(0.64, substantial agreement) is similar to the κ scores (0.57-0.77, moderate to 
substantial) in the reported literature 36,48-50.  
The 20% positive staining cut-off has also been used for a variety of IHC 
biomarkers. These include, Ki-67 as a prognostic biomarker in breast carcinoma 
51 and NF-E2 in the differentiation of essential thrombocythemia from primary 
myelofibrosis 52. However, studies investigating the variation in interpretation of 
this cut-off between pathologists are very limited. The current study 
investigated the 20% cut-off for observer agreement and our results suggested a 
good level of agreement.  
Moderate to strong staining intensity and any percentage of positive cells 
(+2/+3) as a cut-off has also been used for IHC biomarkers.  These include CK20, 
P53, CK5/6, CD138, and Her2/Neu in the diagnosis of urothelial carcinoma in situ 
and the use of claudin-4 to distinguish adenocarcinoma from malignant 
mesothelioma in effusion cytology 26,53,54. However, once again studies observing 
the variation in interpretation of this cut-off between pathologists are very 
limited. Our results demonstrate that this cut-off is also reliable, reproducible 
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and easy to score and it can be ranked second to the 10% cut-off from the 
current study.  
The observer agreement was also assessed using staining in different cellular 
compartments. Staining in only the cytoplasmic compartment achieved higher 
agreements than other staining patterns.  
The interpretation of membranous staining for HER2 in breast cancer is used in 
routine clinical practice. Hameed et al 8 investigated inter-observer agreement 
using 10% positive cells with membranous staining for HER2 in breast cancer. The 
authors found a mean inter-observer agreement κ score of 0.49 8. We also 
investigated inter-observer agreement using 10% positive cells with membranous 
staining for mesothelin in pancreatic cancer and observed κ score agreement of 
0.62. Thus 10% cut-off and membranous staining achieve reasonable observer 
agreement not only for HER2 in breast cancer but for other biomarker in a 
different cancer and warrants further investigations. 
The sample size was good and seven pathologists participated in the present 
study. This number is comparable to the IHC biomarker and histopathology 
literature (4 to 7 participants) where observer agreement was investigated 44,55-
57. In addition, the participants in the current study were practising pathologists 
with variable levels of experience as compared to studies where either 
physicians (with no formal pathology experience) 44 or researchers with 
experience in IHC were recruited 56. Thus the results of this study provide good 
evidence on the use of cut-offs for IHC biomarkers. 
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The limitations include: the relatively few number of images due to the time 
constraints imposed by the clinical work of the pathologists; and all pathologists 
were from the same institution; the aim was to carry out the study with all of 
the pathologists present at one session and this was achieved for the inter-
observer part but for the intra-observer part we had to arrange an extra session. 
An important limitation results from the fact that images were shown as a 
PowerPoint presentation on screen rather than using a standard microscope.  
Conclusions 
 In a day-to-day clinical practice pathologists need scoring systems and cut-offs 
that are reproducible and easy to use 1,8.  A wide range of cut-offs have been 
used for IHC biomarkers. We selected 10%, 20% and +2/+3 cut-offs that have 
been utilised previously in clinical practice. These three cut-offs are reliable and 
reproducible achieving a reasonably good agreement level between pathologists 
(when compared with the literature). They could facilitate translational 
biomarker studies and could potentially be used by scientists who are not 
trained pathologists but are involved in investigating IHC biomarkers. A 
biomarker achieving diagnostic, prognostic and/or predictive significance with 
any of the three cut-offs may have translational potential. Further studies are 
required to assess these cut-offs with pathologists from different institutions and 
using a larger sample of images.  
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Abbreviations  
IHC: Immunohistochemistry 
10% cut-off: 10% positive epithelial cells  
20% cut-off: 20% positive epithelial cells   
+2/+3 cut-off: moderate to strong staining intensity with any proportion of 
positive cells 
Κ: Kappa 
ROC: Receiver operating characteristic curve 
HER2: Human epidermal growth factor receptor 2 
ER: Oestrogen receptor 
PR: Progesterone receptor 
H-score: Histoscore 
CN: Cytoplasmic and/or nuclear staining 
CM: Cytoplasmic and/or membranous staining 
CK7: Cytokeratin 7 
CK20: Cytokeratin 20 
TTF1: Thyroid transcription factor 1 
HMGI: High-mobility group protein I 
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Tables 
Table 1: Pairwise k scores of inter-observer agreements between pathologists for the three 
cut-offs. 
Note: Comparison of pairwise k scores with colour codes between pathologists (A-G) in the 
evaluation of immunohistochemistry using 10%, 20% and +2/+3 cut-offs are shown with mean k 
score and 95% CI separately for each cut-off. 
            10% Cut-Off 
Observers 
O
bs
er
ve
rs
 
  A B C D E F G 
A   0.8 0.82 0.62 0.47 0.72 0.89 
B     0.82 0.62 0.47 0.53 0.89 
C       0.48 0.36 0.58 0.72 
D         0.48 0.55 0.72 
E           0.74 0.54 
F             0.6 
G               
  Mean k score   0.64 (95% CI, 0.57-0.70) 
             20% Cut-Off 
Observers 
O
bs
er
ve
rs
 
  A B C D E F G 
A   0.85 0.57 0.64 0.54 0.49 0.92 
B     0.7 0.53 0.43 0.38 0.77 
C       0.64 0.42 0.48 0.51 
D         0.62 0.82 0.56 
E           0.71 0.46 
F             0.42 
G               
 Mean k score 0.59 (95% CI, 0.52-0.66) 
           +2/+3 Cut-Off 
Observers 
O
bs
er
ve
rs
 
  A B C D E F G 
A   0.75 0.42 0.6 0.55 0.46 0.65 
B     0.48 0.54 0.49 0.52 0.59 
C       0.55 0.61 0.72 0.61 
D         0.58 0.6 0.7 
E           0.88 0.88 
F             0.77 
G               
  Mean k score 0.62 (95% CI, 0.56-0.67) 
  1 
Table 2: Pairwise k scores of inter-observer agreements between experienced and junior pathologists for the three cut-offs. 
A, Comparison of pairwise K scores with 
colour codes between experienced 
pathologists (A-C) in the evaluation of 
immunohistochemistry using 10%, 20% 
and +2/+3 cut-offs shown with mean k 
score and 95% CI separately for each 
cut-off.  
B, Comparison of pairwise K scores with 
colour codes between junior pathologists 
(D-G) in the evaluation of 
immunohistochemistry using 10%, 20% 
and +2/+3 cut-offs shown with mean k 
score and 95% CI separately for each 
cut-off. 
A 
    
B 
    Experienced pathologists 
 
Junior pathologists 
10% Cut-Off 
 
10% Cut-Off 
 Observers   
Observers 
O
bs
er
ve
rs
   A B C 
O
bs
er
ve
rs
   D E F G 
A   0.80 0.82 
 
D   0.48 0.55 0.72 
B   
 
0.82 
 
E   
 
0.74 0.54 
        
 
F   
  
0.60 
        
 
G         
 Mean K score 0.81 (Range: 0.80-0.82) 
 
 Mean k score 0.61 (Range: 0.48-0.74) 
20% Cut-Off 
 
20% Cut-Off 
Observers  Observers 
O
bs
er
ve
rs
   A B C 
 
O
bs
er
ve
rs
   D E F G 
A   0.85 0.57 
 
D   0.62 0.82 0.56 
B   
 
0.70 
 
E   
 
0.71 0.46 
        
 
F   
  
0.42 
        
 
G         
 Mean K score 0.71 (Range: 0.57-0.85) 
 
 Mean k score 0.60 (Range: 0.42-0.82) 
+2/+3 Cut-Off 
 
+2/+3 Cut-Off 
Observers  Observers 
O
bs
er
ve
rs
   A B C 
 
O
bs
er
ve
rs
   D E F G 
A   0.75 0.42 
 
D   0.58 0.60 0.7 
B   
 
0.48 
 
E   
 
0.88 0.88 
        
 
F   
  
0.77 
        
 
G         
 Mean K score 0.55 (Range: 0.42-0.75) 
 
 Mean k score 0.73 (Range: 0.58-0.88) 
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Table 3: Mean k scores with p values for staining of different cellular compartments. 
 
C vs. CN C vs. CM CN vs. CM 
Cut-Offs mean p value* mean p value mean p value 
10% 0.77 vs. o.71 0.380 0.77 vs. 0.64 0.150 0.71 vs. 0.64 0.500 
20% 0.75 vs. 0.63 0.100 0.75 vs. 0.40 <0.001 0.63 vs. 0.40 0.009 
+2/+3 0.81 vs. 0.58 0.001 0.81 vs. 0.40 <0.001 0.58 vs. 0.40 0.010 
Note: *Paired sample t test 
Abbreviations: C (cytoplasmic staining), CM (cytoplasmic and membranous staining) and CN 
(cytoplasmic and nuclear staining). 
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Table 4: Multivariable linear regression for 10%, 20% and +2/+3 cut-offs as predictor 
variables and perceived ease of interpretation as dependent variable. 
Variables Unstandardized 
Coefficients 
Standardized 
Coefficients 
P value 
B Std. Error Beta 
(Constant) -5.67 1.07   <0.001 
10% Cut-off 0.71 0.16 0.41 <0.001 
+2/+3 Cut-off 0.46 0.12 0.38 0.001 
20% Cut-off 0.51 0.16 0.34 0.004 
Note: The 10%, 20% and +2/+3 are predictor variables i.e. they are variables that are predicting an 
outcome (the ease of interpretation). In this regression model ease of interpretation is a dependent 
variable i.e. a variable which “depends” on the predictor variable. The standardised beta 
coefficients were used as an estimate of association between predictor and dependent variable. 
The higher the beta coefficient the higher is the p-value significance and the stronger is the 
association between predictor and dependent variables. Beta coefficient in this model is highest 
(0.41) for 10% cut-off, followed by +2/+3 (0.38) and 20% (0.34). However, the p-value for all three 
cut-offs is significant showing a positive association with ease of interpretation. 
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Table 5: Pairwise k scores of intra-observer agreements for pathologists for the three cut-
offs. 
                                               K Scores 
Codes 10% P value 20% P value +2/+3 P value 
A-A 0.76 <0.001 0.74 <0.001 0.80 <0.001 
B-B 0.89 <0.001 0.68 <0.001 0.72 <0.001 
C-C 0.84 <0.001 0.59 <0.001 0.50 0.003 
D-D 0.43 0.002 0.55 0.001 0.59 <0.001 
E-E 0.68 <0.001 0.59 <0.001 0.88 <0.001 
F-F 0.47 0.003 0.51 0.002 0.94 <0.001 
G-G 0.87 <0.001 0.53 0.001 0.68 <0.001 
Mean 
(95% CI) 
0.71  
(0.53-0.88)   
0.60  
(0.52-0.68)   
0.73  
(0.59-0.87)   
Note: Pairwise k scores showing intra-observer reproducibility from scoring and re-scoring (for 
example A-A) of all seven pathologists (A-G) in the evaluation of Immunohistochemistry using 10%, 
20% and +2/+3 cut-offs. 
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Figure Legends: 
 
Figure 1: Representative images of high and low inter-observer agreement 
between all pathologists for 10%, 20% and +2/+3 cut-offs. 
 
Figure 1 legend: The high (left column grid) and low (right column grid) inter-
observer agreement of IHC interpretation is shown for the three cut-offs. The 
staining for the three cut-offs was recorded only in the tumour epithelium. The high 
level agreement is attributed to the strong staining intensity and higher proportion 
of positive cells as illustrated in left column grid. All pathologists agreed on the 
images in the left column grid for all three cut-offs. However, there were 
differences in the number of pathologists agreeing on the images in the right 
column grid. For 10% cut-off (right upper image) 4/7 pathologists agreed, for 20% 
cut-off (right middle image) 5/7 pathologists agreed and for the +2/+3 cut-off (right 
lower image) 3/7 pathologists agreed. 
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Figure 1: Representative images of high and low inter-observer agreement between all 
pathologists for 10%, 20% and +2/+3 cut-offs. 
 
 
 
 
 
 
